hit counter
Akers Biosciences, Inc. (AKER) Stock News Sentiment & Price - Sentifly
AKER - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Akers Biosciences, Inc. (AKER)

USA
Medical Instruments & Supplies
NASDAQ
AKER Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AKER Latest news
Business Wire
Neutral
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
2021-04-16 12:30

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger

Business Wire
Neutral
Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Plans to Initiate COVID-19 Inflammatory Depression Trial
2021-04-13 09:00

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (NASDAQ: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that thi

Business Wire
Neutral
Akers' Proposed Merger Partner MyMD Pharmaceuticals Announces Formation of Scientific Advisory Board
2021-04-12 09:00

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Ne

Business Wire
Neutral
Akers Biosciences Announces Shareholder Meeting to Vote on Business Combination with MyMD Pharmaceuticals
2021-03-22 08:00

BALTIMORE & THOROFARE, N.J.--(BUSINESS WIRE)--Akers Biosciences, Inc (Nasdaq: AKER), today announced that it has scheduled its general meeting of shareholders (the "Meeting”) to vote on the proposed business combination with MyMD Pharmaceuticals (“MyMD”). The meeting will be held on April 15, 2021 at 10:00 a.m., Eastern Time, and will be “virtual,” meaning that you can participate in the meeting online at www.virtualshareholdermeeting.com/AKER2021SM. In connection with the Meeting, Akers' board

PRNewsWire
Neutral
SHAREHOLDER ALERT: WeissLaw LLP Reminds NTWN, TLRY, CBLI, and AKER Shareholders About Its Ongoing Investigations
2021-03-12 15:31

NEW YORK, March 12, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:                                                                                  CONTACT:                                                                           Joshua Rubin, Esq.                                                                               WeissLaw LLP                                                                    1500 Broadway, 16th Floor                                                                        New York, NY  10036                                                                             (212) 682-3025                                                                             (888) 593-4771                                                                   stockinfo@weisslawllp.com Newtown Lane Marketing, Inc. (OTC: NTWN) WeissLaw LLP is inve

Benzinga
Positive
Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers
2021-02-23 13:25

Akers Biosciences Inc (NASDAQ: AKER) and its proposed merger partner MyMD Pharmaceuticals Inc have announced new data for MYMD-1 from the Eurofins Discovery Phenotypic Center of Excellence study. MYMD-1 is being evaluated for autoimmune and age-related diseases.

Business Wire
Neutral
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery
2021-02-23 09:00

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced new data from a study conducted by Eurofins Discovery Phenotypic Center of Excellence. MYMD-1 is being developed to treat autoimmune and age-related diseases, including extending the human lifespan, and has been

Business Wire
Neutral
Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission
2021-02-18 09:00

BALTIMORE--(BUSINESS WIRE)--Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. (“MyMD”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced a new study published in PLOS ONE authored by Adam Kaplin, M.D., Ph.D., Chief Scientific Officer of MyMD Pharmaceuticals, which demonstrates rising temperatures during spring and summer months are associated with

Business Wire
Neutral
Akers Biosciences Responds to Erroneous Earnings Call Press Release
2021-02-17 13:45

NEW YORK--(BUSINESS WIRE)--Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the newswire services under the Company's name. The Company has not scheduled any earnings calls. The Company is investigating how this error occurred and reserves all rights to pursue all appropriate remedies upon learnin

PRNewsWire
Neutral
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies - AKER, INFO, SNSS, WORK, WDR
2020-12-19 16:55

NEW YORK, Dec. 19, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Akers Biosciences, Inc. (NASDAQ: AKER) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties...

Loading more news...